Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.480 -0.080 (-2.25%)
Official Closing Price Updated: 4:00 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Nvidia-Backed Recursion Pharma Soars After-Hours As FDA Eyes AI Over Animal Testing For Drugs: Retail Traders Elated ↗
Recursion is a clinical-stage biotech firm using AI, machine learning, and automation to accelerate drug discovery. 
Via Stocktwits
Topics Animal Testing Artificial Intelligence
News headline image
Wondering what's happening in today's after-hours session? ↗
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements ↗
Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing... 
Via Benzinga
Topics Animal Testing
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Recursion Pharmaceuticals Stock Is Sinking Today ↗
Via The Motley Fool
News headline image
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March ↗
Via The Motley Fool
Topics Bankruptcy Economy World Trade
News headline image
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today ↗
Via The Motley Fool
Topics Government World Trade
News headline image
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks? ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy. 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock ↗
Fiserv recently completed its acquisition of Payfare Inc. On "Mad Money Lightning Round," Jim Cramer called it "one of the greatest fintechs." 
Via Benzinga
News headline image
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip ↗
Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX. 
Via Benzinga
News headline image
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today ↗
Via The Motley Fool
News headline image
This Biotech Stock Could Be the Best Investment of the Decade ↗
The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits. 
Via The Motley Fool
News headline image
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip? ↗
Via The Motley Fool
News headline image
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says ↗
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham. 
Via Benzinga
News headline image
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip ↗
Leerink cited concerns over high cash burn and execution risks in deal-making and clinical development over the next year. 
Via Stocktwits
News headline image
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday ↗
Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Earnings Scheduled For February 28, 2025 ↗
 
Via Benzinga
News headline image
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?
Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery. 
Via MarketBeat
Topics Artificial Intelligence Regulatory Compliance
News headline image
SoundHound and Serve Robotics Are Dropping Like a Rock -- Why Nvidia Was the Catalyst ↗
Nvidia sold their stake in some high-flying stocks recently. 
Via The Motley Fool
News headline image
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
The Altitude Lab Fund aims to deliver strong returns to Limited Partners, accelerate the growth of Salt Lake City’s Life Science hub, and enable high potential startups support while federal funding is... 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Altitude Lab Startups Raise $154M in Capital
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones 
From Recursion Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.